Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday. Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research […]
